In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zhejiang Wansheng Pharmaceutical Co. Ltd.

Division of 3SBio Inc.
www.wshpharm.com/index.php/en/about

Latest From Zhejiang Wansheng Pharmaceutical Co. Ltd.

3SBio Acquires Wansheng To Bolster Small Molecule Portfolio

China’s 3SBio has been actively scouting M&A targets in both overseas and domestic markets, aiming to enrich its product pipeline and diversify its offering. It has now landed its first acquisition, of a chemical drug maker in China, just one month after its Hong Kong IPO, in a deal that will provide 3SBio with an integrated small molecule R&D and manufacturing platform and increase its manufacturing cost competitiveness.

BioPharmaceutical China
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Metabolic Disorders
  • Renal System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • 3SBio Inc.
  • Senior Management
  • Luo Xie Long, CEO
  • Contact Info
  • Zhejiang Wansheng Pharmaceutical Co. Ltd.
    Phone: 571 88270801
    10F Bldg. D
    380# Fengtan Rd
    Hangzhou,
    China
UsernamePublicRestriction

Register